Gyre Therapeutics Inc. Unveils Presentation on Anti-Fibrotic Therapeutics for Chronic Organ Diseases

Reuters09-11

<a href="https://laohu8.com/S/GYRE">Gyre Therapeutics</a> Inc. Unveils Presentation on Anti-Fibrotic <a href="https://laohu8.com/S/LENZ">Therapeutics</a> for Chronic Organ Diseases

Gyre Therapeutics Inc. recently presented at the H.C. Wainwright Global Investment Conference in September 2025, highlighting their advancements in developing anti-fibrotic therapeutics for chronic organ diseases. The company has maintained a leading position in China's IPF market since 2011 with their treatment, pirfenidone, holding approximately 50% market share. The presentation also discussed strategic initiatives, including the upcoming launch of Hydronidone and the acquisition of generic drugs Etorel and Contiva to expand their treatment offerings. Gyre Therapeutics continues to focus on their fibrosis-focused development pipeline with candidate F351 (hydronidone) for advanced liver fibrosis currently in IND preparation. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief on September 10, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2566986362?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-11 01:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2566986362","market":"fut","top_or_hot":-1,"title":"Gyre Therapeutics Inc. Unveils Presentation on Anti-Fibrotic Therapeutics for Chronic Organ Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GYRE\">Gyre Therapeutics</a> Inc. Unveils Presentation on Anti-Fibrotic <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for Chronic Organ Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Gyre Therapeutics Inc. recently presented at the H.C. Wainwright Global Investment Conference in September 2025, highlighting their advancements in developing anti-fibrotic therapeutics for chronic organ diseases. The company has maintained a leading position in China's IPF market since 2011 with their treatment, pirfenidone, holding approximately 50% market share. The presentation also discussed strategic initiatives, including the upcoming launch of Hydronidone and the acquisition of generic drugs Etorel and Contiva to expand their treatment offerings. Gyre Therapeutics continues to focus on their fibrosis-focused development pipeline with candidate F351 (hydronidone) for advanced liver fibrosis currently in IND preparation. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gyre Therapeutics Inc. Unveils Presentation on Anti-Fibrotic Therapeutics for Chronic Organ Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGyre Therapeutics Inc. Unveils Presentation on Anti-Fibrotic Therapeutics for Chronic Organ Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-11 01:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/GYRE\">Gyre Therapeutics</a> Inc. Unveils Presentation on Anti-Fibrotic <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> for Chronic Organ Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Gyre Therapeutics Inc. recently presented at the H.C. Wainwright Global Investment Conference in September 2025, highlighting their advancements in developing anti-fibrotic therapeutics for chronic organ diseases. The company has maintained a leading position in China's IPF market since 2011 with their treatment, pirfenidone, holding approximately 50% market share. The presentation also discussed strategic initiatives, including the upcoming launch of Hydronidone and the acquisition of generic drugs Etorel and Contiva to expand their treatment offerings. Gyre Therapeutics continues to focus on their fibrosis-focused development pipeline with candidate F351 (hydronidone) for advanced liver fibrosis currently in IND preparation. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief on September 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GYRE","symbol_name":"Gyre Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250910:nNDL27XJK6:1","article_id":"2566986362","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2566986362","pubTimestamp":1757524707,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Gyre Therapeutics Inc. recently presented at the H.C. Wainwright Global Investment Conference in September 2025, highlighting their advancements in developing anti-fibrotic therapeutics for chronic organ diseases. The company has maintained a leading position in China's IPF market since 2011 with their treatment, pirfenidone, holding approximately 50% market share. The presentation also discussed strategic initiatives, including the upcoming launch of Hydronidone and the acquisition of generic drugs Etorel and Contiva to expand their treatment offerings. Gyre Therapeutics continues to focus on their fibrosis-focused development pipeline with candidate F351  for advanced liver fibrosis currently in IND preparation. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GYRE":"Gyre Therapeutics","BK4139":"生物科技"},"translate_title":"Gyre Therapeutics Inc.推出针对慢性器官疾病的抗纤维化疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GYRE":0.9},"content_text":"Gyre Therapeutics Inc. Unveils Presentation on Anti-Fibrotic Therapeutics for Chronic Organ Diseases\n    \n\n        Gyre Therapeutics Inc. recently presented at the H.C. Wainwright Global Investment Conference in September 2025, highlighting their advancements in developing anti-fibrotic therapeutics for chronic organ diseases. The company has maintained a leading position in China's IPF market since 2011 with their treatment, pirfenidone, holding approximately 50% market share. The presentation also discussed strategic initiatives, including the upcoming launch of Hydronidone and the acquisition of generic drugs Etorel and Contiva to expand their treatment offerings. Gyre Therapeutics continues to focus on their fibrosis-focused development pipeline with candidate F351 (hydronidone) for advanced liver fibrosis currently in IND preparation. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gyre Therapeutics Inc. published the original content used to generate this news brief on September 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2566986362","isCrawlerRequest":true}